In 2019, sales of branded biologics in ophthalmology reached almost $9 billion across the major markets (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for these two key reference brands and their biosimilars by molecule and region.

Table of contents

  • Biosimilars - Market Events And Forecast - Ophthalmology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Ophthalmology Biologics
      • Terminology
      • Overarching Forecast Assumptions
        • Overview of Ophthalmology Biological Brands in Forecast
          • Overview of Approved Ophthalmology Biologics
          • Biosimilar Entry Assumptions for Ophthalmology Biologics
        • Overview of Biosimilars in Ophthalmology Disease Assumptions
        • Drug-Specific Forecast Assumptions
          • Lucentis
            • Outlook for Lucentis
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Lucentis Sales Forecast for the United States: 2019-2029
            • Lucentis Sales Forecast for the EU5: 2019-2029
            • Lucentis Sales Forecast for Japan: 2019-2029
          • Eylea
            • Outlook for Eylea
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturing Price Assumptions
            • Eylea Sales Forecast for the United States: 2019-2029
            • Eylea Sales Forecast for the EU5: 2019-2029
            • Eylea Sales Forecast for Japan: 2019-2029

      Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

      Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

      Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.